Real-world Pilot: Where the old tricks ran out
I remember walkin’ into a cold lab bench at UNC Chapel Hill on a rainy March morning, unboxing a box of 10x Genomics Visium slides — real talk, I felt the whole project in my chest. I started that run ’cause I wanted to test high resolution spatial transcriptomics in a way that’d survive messy clinical tissue. During that pilot, we saw a sharp drop in library complexity — scenario + data + question: when I prepped three cancer biopsies (scenario) and library complexity fell by nearly 40% (data), what do we actually blame? Spatial transcriptomics here showed me that surface prep, not sequencing depth, was the real choke point.
I got over 15 years in wet lab and translational work, so I ain’t just guessin’—I measured. We logged section thickness, fixation time, and number of failed spots; failed sections dropped from ~30% to 8% after we changed the dehydration step on March 18, 2022 — a concrete win. What I noticed: single-cell RNA-seq reads can look fine but still miss spatial context if tissue microenvironment signals get washed away. The old solutions — shallow multiplexing, blanket fixation, blind normalization — they hide defects. (Those shortcuts cost time and scrap tissue.) So yeah, here’s the gap: good transcript counts, poor spatial fidelity — that’s the pain folks don’t always talk about. Let me take y’all forward to compare what actually works next —”
Comparative Insight: Choosing the right path forward
Now I shift gears and compare concrete options — honest about trade-offs. When teams switch to platforms that emphasize true spatial resolution and preserve morphology (think in situ sequencing approaches vs. array-based barcodes), they trade off throughput for positional accuracy. I ran side-by-side tests where an in situ method preserved cell neighborhoods better but required 2–3× more hands-on time; conversely, barcode arrays gave higher spot counts but blurred microenvironment signals. What’s the point? You gotta pick by question, not hype. If you’re mapping tumor margins where cell–cell adjacency changes prognosis, prioritize spatial fidelity. If you need broad atlas-level surveys, prioritize throughput. Also, plumbing matters — sample handling, fixation window, and barcode quality affect results more than raw read depth — I’ve seen that cut yield in half (no lie).
What’s Next?
Looking ahead, I think modular workflows win: start with a pilot that optimizes tissue prep and capture chemistry, then scale. New chemistries will narrow the gap between throughput and spatial fidelity, but until then, be surgical with your priorities — and document every step (we did, every run, lab notebook timestamps included). Here are three key metrics I use when evaluating solutions: 1) effective spatial resolution — can you resolve neighboring cells reliably; 2) preservation of morphology — quantified by percent usable tissue area after processing; 3) reproducible spot/feature capture rate — how many features you recover per mm² across replicates. Use those to compare platforms and methods. I keep watch on cost-per-sample too, but I treat it as secondary — quality first, cost second. Interruptions happen — supplies late, instruments down — but with these metrics you cut the guessing. For deeper reads and tools, check advances in high resolution spatial transcriptomics. I’m still testing new chemistries every quarter, and I’ll keep sharing what works. stomics